| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23N3O4S |
| Molecular Weight | 341.426 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O
InChI
InChIKey=BGRJTUBHPOOWDU-UHFFFAOYSA-N
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
Sulpiride is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Europe, Russia and Japan. Sulpiride is a selective antagonist at dopamine D2 and D3 receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Racemic and L-sulpiride significantly decreased stimulated serum gastrin concentration, but they did not affect fasting serum gastrin or basal and stimulated gastric acidity. D-sulpiride significantly decreased gastric acid secretion, without affecting serum gastrin levels.
CNS Activity
Approval Year
Sample Use Guides
400mg twice daily the doctor may reduce the dose to 200mg twice daily or increase it to a maximum of 1200mg twice daily
Route of Administration:
Oral
CHO-K1 D3R cells (DiscoveRx) were seeded at a density of 5000 cells/well in 384-well black, clear-bottom plates. Following 24 h of incubation, the cells were treated with multiple concentrations of the Sulpiride (0-10 μM) in Hanks’ balanced buffer solution containing 2% DMSO. Following a 10 min preincubation, the cells were next treated with an EC95 dose of dopamine (100 nM) and then incubated at 37 C for 90 min. DiscoveRx reagent (2.5) was then added to cells followed by a 60 min incubation at room temperature. Luminescence was measured on a Hamamatsu FDSS μ-cell reader.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
